0000899243-21-044603.txt : 20211115
0000899243-21-044603.hdr.sgml : 20211115
20211115170023
ACCESSION NUMBER: 0000899243-21-044603
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211111
FILED AS OF DATE: 20211115
DATE AS OF CHANGE: 20211115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Suri Anish
CENTRAL INDEX KEY: 0001739130
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38327
FILM NUMBER: 211412031
MAIL ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cue Biopharma, Inc.
CENTRAL INDEX KEY: 0001645460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473324577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-949-2680
MAIL ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Imagen Biopharma, Inc.
DATE OF NAME CHANGE: 20150617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-11
0
0001645460
Cue Biopharma, Inc.
CUE
0001739130
Suri Anish
C/O CUE BIOPHARMA, INC.
21 ERIE STREET
CAMBRIDGE
MA
02139
0
1
0
0
President and CSO
Common Stock
2021-11-11
4
M
0
20000
6.42
A
114038
D
Common Stock
2021-11-11
4
S
0
20000
15.0677
D
94038
D
Stock Option (right to buy)
6.42
2021-11-11
4
M
0
20000
0.00
D
2029-03-06
Common Stock
20000
105000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
The option vests in eight equal semi-annual installments beginning September 6, 2019.
/s/ Anish Suri by Colin Sandercock, attorney-in-fact
2021-11-15